Pacific Edge was formed in February 2001 with the goal of developing simple-to-use, non-invasive, highly accurate diagnostic and prognostic tools for cancer. The early years of the company were focused on research and development from which to create a product pipeline. In addition, the company has been vigilant regarding formal protection of intellectual property to underpin the value of the products developed. As a result of a successful development programme, Pacific Edge currently has a pipeline of products for the early detection and management of targeted cancers. The first of these products, Cxbladder®, was launched in the New Zealand and Australian markets in 2010.